A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)
Por:
González A, Lluch A, Aba E, Albanell J, Antón A, Álvarez I, Ayala F, Barnadas A, Calvo L, Ciruelos E, Cortés J, de la Haba J, López-Vega JM, Martínez E, Muñoz M, Peláez I, Redondo A, Rodríguez Á, Rodríguez CA, Ruíz A and Llombart A
Publicada:
1 may 2017
Ahead of Print:
16 nov 2016
Resumen:
To converge on an expert opinion to define aggressive disease in
patients with HER2-negative mBC using a modified Delphi methodology.
A panel of 21 breast cancer experts from the Spanish Society of Medical
Oncology agreed upon a survey which comprised 47 questions that were
grouped into three sections: relevance for defining aggressive disease,
aggressive disease criteria and therapeutic goals. Answers were rated
using a 9-point Likert scale of relevance or agreement.
Among the 88 oncologists that were invited to participate, 81 answered
the first round (92%), 70 answered the second round (80%), and 67
answered the third round (76%) of the survey. There was strong agreement
regarding the fact that identifying patients with aggressive disease
needs to be adequately addressed to help practitioners to decide the
best treatment options for patients with HER2-negative mBC. The factors
that were considered to be strongly relevant to classifying patients
with aggressive HER2-negative mBC were a high tumor burden, a
disease-free interval of less than 12-24 months after surgery, the
presence of progressive disease during adjuvant or neoadjuvant
chemotherapy and having a triple-negative phenotype. The main
therapeutic goals were controlling symptoms, improving quality of life
and increasing the time to progression and overall survival.
High tumor burden, time to recurrence after prior therapy and having a
triple-negative phenotype were the prognostic factors for which the
greatest consensus was found for identifying patients with aggressive
HER2-negative mBC. Identifying patients with aggressive disease leads to
different therapeutic approaches.
Filiaciones:
González A:
Medical Oncology Department, MD Anderson Cancer Center, C/Arturo Soria, 270, 28033, Madrid, Spain.
Lluch A:
Hematology and Oncology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain
Aba E:
Medical Oncology Department, Hospital Universitario Virgen de la Victoria, Málaga, Spain
Albanell J:
Medical Oncology Department, Hospital Parc de Salut Mar, Barcelona, Spain
Antón A:
Medical Oncology Department, Hospital Miguel Servet, Zaragoza, Spain
Álvarez I:
Medical Oncology Department, Hospital Universitario Donostia, San Sebastián, Spain
Ayala F:
Medical Oncology Department, Hospital Universitario Morales Meseguer, Murcia, Spain
Barnadas A:
Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Calvo L:
Medical Oncology Department, Complejo Hospitalario Universitario de La Coruña, La Coruña, Spain
Ciruelos E:
Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain
Cortés J:
Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain
de la Haba J:
Medical Oncology Department, Hospital Universitario Reina Sofía, Córdoba, Spain
López-Vega JM:
Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain
Martínez E:
Medical Oncology Department, Fundación Hospital Provincial de Castellón, Castellón, Spain
Muñoz M:
Medical Oncology department, Hospital Clínic de Barcelona, Barcelona, Spain
Peláez I:
Medical Oncology Department, Hospital de Cabueñes, Gijón, Spain
Redondo A:
Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain
:
Medical Oncology Department, Hospital General Universitario de Elche, Elche, Spain
Rodríguez CA:
Medical Oncology Department, Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain
Ruíz A:
Instituto Valenciano de Oncología, Valencia, Spain
Llombart A:
Medical Oncology Department, Hospital Universitario Arnau Vilanova, Lleida, Spain
|